The Bellvitge Biomedical Research Institute (IDIBELL) is a research center in biomedicine promoted by the Bellvitge University Hospital and l’Viladecans Hospital, both from the Catalan Health Institute, the Catalan Institute of Oncology, University of Barcelona and L’Hospitalet de Llobregat city council. In 2017, the Center for Regenerative Medicine of Barcelona (CMR[B]), now part of IDIBELL, launched the Program for Advancing the Clinical Translation of Regenerative Medicine of Catalonia (P-CMR[C]) together with IDIBELL.
IDIBELL research is focused in cancer, neuroscience, translational medicine and regenerative medicine. Research, innovation and society are the axes on which researchers work every day with the goal of improving the quality of life of citizens.
IDIBELL is placed in L'Hospitalet de Llobregat, at the south of Barcelona. The center is certified as a health research institute by the Instituto de Salud Carlos III; is also member of Campus d'Excel·lència Internacional de la Universitat de Barcelona HUBc and the Institut CERCA from the Generalitat de Catalunya. Additionally, the institute has received the 'HR Excellence in Research' seal from the European Comission.